Search

Author/Creator Plevris, N

2. P471 Association of vedolizumab levels with clinical and biochemical markers of inflammation during maintenance therapy in inflammatory bowel disease. (25th January 2019)

Authors:
Plevris, N; Jones, G R; Jenkinson, P W; Chuah, C S; Lyons, M; Merchant, L M; Pattenden, R J; Arnott, I D; Lees, C W
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S347
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P225 Day of admission results predict failure of first-line treatment in acute ulcerative colitis. (25th January 2019)

Authors:
Grant, R; Lynch, R; Bouri, S; Elosua González, A; Manship, T; Jagger, F; Shivakumar, M; Satsangi, J; Ho, G-T; Lees, C; Plevris, N; Tozer, P; Hart, A; Arnott, I
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S209
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. DOP87 Multi-parameter datasets are required to identify the true prevalence of IBD: The Lothian IBD Registry (LIBDR). (25th January 2019)

Authors:
Jones, G-R; Lyons, M; Plevris, N; Jenkinson, P; Bisset, C; Fulforth, J; Chuah, C S; Minnis, S; Gillespie, S-L; Brindle, W; Burgess, C; Henderson, P; Wilson, D; Lees, C
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S082
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn's Disease: Correlations Between Disease Activity and Long-Term Follow-Up. (19th November 2018)

Authors:
Jones, G R; Fascì-Spurio, F; Kennedy, N A; Plevris, N; Jenkinson, P; Lyons, M; Wong, L; MacLean, P; Glancy, S; Lees, C W
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13:Number 4(2019)
Page Start:
442
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. DOP072 Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn's disease cohort. (16th January 2018)

Authors:
Plevris, N; Jenkinson, P; Chuah, C S; Lyons, M; Hall, R; Jones, G; Watson, E; Arnott, I; Lees, C
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S079
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P399 Vedolizumab therapy results in reduced hospitalisation and steroid use over 1-year: Results from the Scottish vedolizumab consortium. (16th January 2018)

Authors:
Plevris, N; Chuah, C S; Allen, R; Baker, P; Brennan, P; Churchhouse, A; Donoghue, E; Gaya, D; Jafferbhoy, H; Jenkinson, P; Jones, G; Macdonald, J; MacMaster, M; Mowat, C; Naismith, G; Potts, L; Saffouri, E; Seenan, J P; Sengupta, A; Shasi, P
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S306
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P713 Effects of vedolizumab on health-related quality of life, work productivity and patient concerns in patients with ulcerative colitis and Crohn's disease in the UK and Ireland: OCTAVO cohort 2. (15th January 2020)

Authors:
Parkes, G; Akbar, A; Beales, I; Buckley, M; Creed, T; Din, S; Fraser, A; Plevris, N; Meadowcroft, S; Owen, G; Heggs, N
Journal:
Journal of Crohn's and colitis
Issue:
Volume 14(2020)Supplement 1
Page Start:
S575
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗